胰岛素联合罗格列酮或二甲双胍治疗对2型糖尿病患者血清hCRP的影响

Effects of insulin plus rosiglitazone or plus metformin on serum high C reaction protein in type 2 diabetes mellitus.

目的了解胰岛素联合罗格列酮或二甲双胍治疗对2型糖尿病患者血清hCRP水平的影响。方法将符合纳入标准的2型糖尿病患者60例,随机分成A,B两组。A组给予胰岛素联合罗格列酮(4mg/d,n=30)治疗,B组给予胰岛素联合二甲双胍治疗(n=30),共8周,治疗前后分别测空腹血糖、餐后2h血糖、糖化血红蛋白及血清hCRP等。结果胰岛素联合罗格列酮或二甲双胍治疗,均能降低血糖和糖化血红蛋白(P<0.05)。治疗前后,罗格列酮组hCRP水平降低了1.8mg/L,二甲双胍组hCRP水平降低了0.9mg/L,但均未达到统计学意义(P>0.05)。结论罗格列酮或二甲双胍在胰岛素治疗2型糖尿病患者的基础上,对血清hCRP水平进一步降低作用不明显。

Objective To observe the effects of insulin plus rosiglitazone and insulin plus meffomain on serum high C reaction protein（hCRP） in type 2 diabetes mellitus. Methods Sixty type 2 diabetic patients were recruited and divided into group A and group B randomly. Group A（ n = 30） received insulin plus rosiglitazone（4mg/d）, group B（n = 30） received insulin plus meffomain. The trial consisted for an 8 week course of treatment. The fasting blood glucose（FBG）, postprandial plasma glucose（PPG）, HbA1c and serum hCRP were measured at the beginning and at the end of the trial. Results The results showed the level of FBG, PPG and HbA1 c decreased obviously（ P 〈 0.05） in boty insulin plus rosiglitazone group and insulin plus meffomain group. Compared with baseline, the mean level of hCRP decreased 1.8mg/L in rosiglitazone group, and 0.9mg/L in meffomain group, respectively, but the deference has not statistical significance（ P 〉 0.05 ）. Conclusion Rosiglitazone or meffomain can not decrease tile level of serum hCRP in type2 diabetes mellitus on the basis of insulin therapy.